Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Aug;10(2):241–244. doi: 10.1128/aac.10.2.241

Comparative Activity In Vitro of Ticarcillin, BL-P1654, and Carbenicillin

Theodore C Eickhoff 1, Josephine M Ehret 1
PMCID: PMC429728  PMID: 984764

Abstract

The activity of ticarcillin, BL-P1654, and carbenicillin was compared in vitro using a microtiter tube dilution test in Mueller-Hinton broth against 50 recent clinical isolates each of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella species, Enterobacter species, Proteus species, and Pseudomonas aeruginosa. Bactericidal end points were determined using a modified Steers replicator. Ticarcillin was generally two to four times more active against all organisms tested except S. epidermidis against which BL-P1654 was most active. Median minimum inhibitory concentrations in micrograms per milliliter were for S. aureus: ticarcillin (6.2), carbenicillin (12.5), BL-P1654 (25); for S. epidermidis: BL-P1654 (1.6), ticarcillin (3.2), carbenicillin (3.2); for E. coli: ticarcillin (3.2), BL-P1654 (6.2), carbenicillin (6.2); for Klebsiella sp.: >100 for all three drugs; for Enterobacter sp.: ticarcillin (3.2), carbenicillin (6.2), BL-P1654 (12.5); for Proteus sp.: ticarcillin (1.6), carbenicillin (1.6), BL-P1654 (3.2); for P. aeruginosa: ticarcillin (31), BL-P1654 (62), carbenicillin (125). Bactericidal end points were dependent on both the drug and the species but were in general no more than twofold more than the minimum inhibitory concentration with the exception of BL-P1654 against P. aeruginosa. BL-P1654 was bactericidal for only 60% of the strains tested at a concentration of 500 μg/ml.

Full text

PDF
241

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Deerhake B. In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol. 1971 Jan;21(1):61–65. doi: 10.1128/am.21.1.61-65.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P., Stewart D. In vitro studies of a new semisynthetic penicillin, 6-(d-alpha-sulfoaminophenylacetamido)-penicillanic acid. Appl Microbiol. 1969 Jul;18(1):76–79. doi: 10.1128/am.18.1.76-79.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown C. H., 3rd, Natelson E. A., Bradshaw M. W., Alfrey C P., Jr, Williams T. W., Jr Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother. 1975 May;7(5):652–657. doi: 10.1128/aac.7.5.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Klastersky J., Henri A., Daneau D. Ticarcillin, a new semisynthetic penicillin active on Pseudomonas aeruginosa: in vitro activity and blood levels in man. J Clin Pharmacol. 1974 Apr;14(4):172–175. doi: 10.1002/j.1552-4604.1974.tb01394.x. [DOI] [PubMed] [Google Scholar]
  5. Kurtz S., Holmes K., Turck M. Disparity between inhibitory and killing effects of BL-P1654. Antimicrob Agents Chemother. 1975 Feb;7(2):215–218. doi: 10.1128/aac.7.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Libke R. D., Clarke J. T., Ralph E. D., Luthy R. P., Kirby W. M. Ticarcillin vs carbenicillin: clinical pharmacokinetics. Clin Pharmacol Ther. 1975 Apr;17(4):441–446. doi: 10.1002/cpt1975174441. [DOI] [PubMed] [Google Scholar]
  7. Neu H. C., Winshell E. B. Semisynthetic penicillin 6-(D(--)-alpha-carboxy-3-thienylacetamido) penicillanic acid active against Pseudomonas in vitro. Appl Microbiol. 1971 Jan;21(1):66–70. doi: 10.1128/am.21.1.66-70.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Overturf G. D., Ressler R., Wilkins J. Comparative in vitro evaluation of BL-P1654 and carbenicillin against Pseudomonas. Antimicrob Agents Chemother. 1974 Nov;6(5):643–646. doi: 10.1128/aac.6.5.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pines A., Khaja G., Raafat H., Sreedharan K. S. Preliminary clinical experience with ticarcillin (BRL 2288) in 101 patients treated for severe respiratory infections. Chemotherapy. 1974;20(1):39–44. doi: 10.1159/000221789. [DOI] [PubMed] [Google Scholar]
  10. Rodriguez V., Bodey G. P., Horikoshi N., Inagaki J., McCredie K. B. Ticarcillin therapy of infections. Antimicrob Agents Chemother. 1973 Oct;4(4):427–431. doi: 10.1128/aac.4.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rodriguez V., Inagaki J., Bodey G. P. Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother. 1973 Jul;4(1):31–36. doi: 10.1128/aac.4.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sanders C. C., Sanders W. E., Jr BL-P1654: a bacteriostatic penicillin? Antimicrob Agents Chemother. 1975 Apr;7(4):435–440. doi: 10.1128/aac.7.4.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wald E. R., Standiford H. C., Tatem B. A., Calia F. M., Hornick R. B. BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1975 Mar;7(3):336–340. doi: 10.1128/aac.7.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wise R., Reeves D. S. Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy. 1974;20(1):45–51. doi: 10.1159/000221790. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES